Mounjaro vs Zepbound: Same Drug, Different Prices

Updated April 20, 2026

Mounjaro and Zepbound are the same active ingredient — tirzepatide — from the same manufacturer — Eli Lilly. They work identically in your body. But they carry different brand names, different FDA-approved indications, and different prices. At April 2026 self-pay rates, Zepbound runs $51/month cheaper than Mounjaro.

This guide explains why that's the case, which one you should take if you have a choice, and when the higher-priced option is actually your better deal.

Quick Answer

Why They're Priced Differently

Eli Lilly launched Mounjaro in 2022 for Type 2 diabetes and Zepbound in 2023 for weight management. Both are tirzepatide, but branding them separately gave Lilly pricing and formulary flexibility. Diabetes drugs have historically been reimbursed at higher rates and included in more insurance formularies; weight-loss drugs have faced more coverage resistance and list-price pressure.

The practical result in 2026:

• Mounjaro's list price is slightly lower ($1,070 vs $1,086) but its self-pay options are higher ($350 TrumpRx, no LillyDirect).
• Zepbound's list price is slightly higher ($1,086 vs $1,070) but its self-pay options are lower ($299 TrumpRx/LillyDirect start).
• Mounjaro has much better commercial insurance coverage because diabetes coverage is broadly mandated; weight-loss coverage is not.

Self-Pay: Zepbound Wins

If you're paying cash, Zepbound is consistently cheaper:

• TrumpRx: Zepbound $299/mo flat vs Mounjaro $350/mo flat — $51/month savings, $612/year.
• LillyDirect: Zepbound $299 starting / $399 at 5mg / $449 at 7.5mg+. Mounjaro is no longer on LillyDirect at all.

At the starting dose, Zepbound on TrumpRx saves $51/mo vs Mounjaro on TrumpRx. At maintenance, Zepbound continues saving $51/mo on TrumpRx ($299) versus Mounjaro ($350).

Insurance: Mounjaro Wins

Commercial insurance coverage is where the tables turn:

• Mounjaro for diabetes: Roughly 82% of commercial plans cover it. If you qualify, the Lilly savings card drops the copay to $25/month.
• Zepbound for weight loss: Only 30–40% of commercial plans cover it. The Lilly savings card still drops the copay to $25/month when covered — but the population of people who qualify is smaller.

If you have Type 2 diabetes and your doctor's choice is between Mounjaro and Zepbound (clinically they work the same), Mounjaro will almost always be the cheaper option when filed under your insurance.

When Mounjaro Is the Right Choice

• You have Type 2 diabetes and commercial insurance that covers Mounjaro. Savings card = $25/month. Clear winner.
• You have Medicare or Medicaid and need tirzepatide for diabetes. Part D or your state Medicaid likely covers Mounjaro; coverage for Zepbound (weight loss indication) is rarer.
• You have obstructive sleep apnea and Type 2 diabetes. Mounjaro's dual approval plus diabetes coverage rates gives you flexibility.

When Zepbound Is the Right Choice

• You're paying self-pay cash. $299 beats $350 at every dose, every month.
• You need it specifically for weight management and have commercial insurance that covers Zepbound. Savings card = $25/month.
• You're income-qualified for patient assistance. Lilly Cares covers Zepbound but NOT Mounjaro. This is a critical gap.
• You have sleep apnea without a diabetes or weight-management diagnosis. Either works clinically, but Zepbound self-pay is cheaper.
• Starting July 2026, you're a Medicare beneficiary with obesity. The Medicare GLP-1 Bridge covers Zepbound at $50/month. Mounjaro isn't in the Bridge.

Clinical Note

Mounjaro and Zepbound are pharmacologically identical. They use the same molecule at the same doses (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg). Anything your doctor can achieve with one, they can achieve with the other. The choice is driven by:

• FDA labeling (your doctor will usually match the drug to your documented indication)
• Insurance coverage (your plan may only cover one)
• Self-pay price (Zepbound wins at cash pricing)

Switching from one to the other mid-treatment is clinically trivial — same molecule, no re-titration — but your insurance may require a new prior authorization, and your savings card year-cap resets.

Bottom Line

• Paying cash? Zepbound at $299 (TrumpRx) beats Mounjaro at $350.
• Commercial insurance + diabetes? Mounjaro likely $25/mo copay. Winner.
• Commercial insurance + weight loss only? Zepbound if your plan covers it ($25/mo); Zepbound self-pay TrumpRx if not.
• Uninsured, income-qualified? Zepbound via Lilly Cares (free). Mounjaro has no PAP.
• Medicare, starting July 2026? Zepbound at $50/mo via GLP-1 Bridge.